Breaking News, Collaborations & Alliances

Incyte, Enable Injections Enter enFuse Partnership

Incyte gains a worldwide license to use enFuse technology with its mutCALR-targeted therapy for ET and MF with the potential to expand indications.

By: Rachel Klemovitch

Assistant Editor

Incyte and Enable Injections announced a new partnership to develop and commercialize specific assets in Incyte’s portfolio, including its investigational, first-in-class mutant calreticulin (mutCALR) selective monoclonal antibody, with Enable’s enFuse On-Body Delivery System. Per the agreement, Incyte will obtain a worldwide, exclusive license to use the enFuse technology in conjunction with its mutCALR-targeted therapy (INCA033989) to treat essential thrombocythemia (ET) and myelofibrosis (...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters